(NYSE: GSK) Gsk's forecast annual revenue growth rate of 2.46% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.71%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Gsk's revenue in 2025 is $41,485,526,315.On average, 4 Wall Street analysts forecast GSK's revenue for 2025 to be $166,062,960,840,000, with the lowest GSK revenue forecast at $160,233,084,480,000, and the highest GSK revenue forecast at $168,334,274,080,000. On average, 4 Wall Street analysts forecast GSK's revenue for 2026 to be $174,674,884,720,000, with the lowest GSK revenue forecast at $174,096,964,160,000, and the highest GSK revenue forecast at $175,357,785,120,000.
In 2027, GSK is forecast to generate $182,162,776,208,000 in revenue, with the lowest revenue forecast at $180,726,637,280,000 and the highest revenue forecast at $183,996,178,800,000.